Send to

Choose Destination
Eur Heart J. 2017 Jun 7;38(22):1728-1737. doi: 10.1093/eurheartj/ehw268.

Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge.

Author information

Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, UK.
Division of Cardiology, Cardiovascular Centre, University Hospital Zurich, Zurich, Switzerland.


Sudden cardiac death (SCD) is the most devastating complication of hypertrophic cardiomyopathy (HCM). Although the annual rate of SCD in the general HCM population is <1% per year according to contemporary series, there is still a small subset of patients who are at increased risk of SCD. The greatest challenge in the management of HCM is identifying those at increased risk as an implantable cardioverter defibrillator is a potentially life-saving therapy. In this review, we sought to summarize the available data on SCD in HCM and provide a clinical perspective on the current differing and somewhat conflicting European and American recommendations on risk stratification, with balanced guidance with regards to rational clinical decision making. Additionally, we sought to learn more on the actual implementation of the guidelines by HCM experts worldwide.


Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; Risk Stratification; Sudden cardiac death

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center